Clinical Trials Logo

Clinical Trial Summary

The World Health Organization (WHO) and the United Nations Children's Fund (UNICEF) recommend that babies be exclusively breastfed for the first 6 months from birth. The composition of breast milk is dynamic and may vary according to the content of maternal nutrition. Maternal nutrition, on the other hand, determines the quality of breast milk necessary for the adequate growth and health of infants. For this reason, the content of the maternal diet is important during the lactation period, which is the critical stage that can affect the development of infants. Omega 3 fatty acids are essential unsaturated fatty acids that are not synthesized by the human body and must be obtained through diet. The polyunsaturated fatty acids (PUFAs) most abundant in the diet are short-chain omega 3 alpha linolenic acid (ALA) and omega 6 linoleic acid (LA), which are mostly found in vegetable oils. ALA is a plant-derived omega 3 fatty acid found in flaxseed, walnut, canola and soybean oils. Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) are found in marine sources such as seafood and fish oils. Today, the use of Omega 3 fatty acid supplements is increasing during the lactation period. However, consumption of omega 3 fatty acid sources during pregnancy or lactation is thought to be an important factor in preventing cancer risk. In our study, the investigators aimed to compare the maternal diet and the consumption of fish oil, flaxseed oil and walnut oil supplements during the lactation period, to compare the amount of prolactin and DHA in the milk composition and to compare the protective effects against breast cancer with cancer stem cell markers. For this study, 32 healthy Wistar pregnant rats, weighing 200-250 g, 8-10 weeks pregnant and not included in any experiments, will be used. Supplementary oils will be administered by oral gavage, considering the 0.5 g/kg body weight of the pregnant rats according to the groups they are assigned to, during the entire standard lactation period (day 21), considering the day of birth of the pregnant rats as the 0th day of lactation. Mother rats will be sacrificed under anesthesia at the end of the 21st day of lactation, mammary tissues will be taken into appropriate solutions and histopathological and immunohistochemical examinations will be performed. In addition, cardiac blood will be drawn and blood and tissue biochemical analyzes will be performed.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06111378
Study type Observational
Source Celal Bayar University
Contact
Status Completed
Phase
Start date June 15, 2022
Completion date August 31, 2023

See also
  Status Clinical Trial Phase
Completed NCT04756089 - Stimulation Therapy for Inducing Mothers N/A
Completed NCT03341481 - Effectiveness of Femaltiker in Stimulation Lactation Among Mothers of Preterm Infants N/A